https://www.selleckchem.com/pr....oducts/1-methyl-3-ni
part/none 47%) who received all of their treatment at a SCC. After adjusting for sociodemographic and clinical factors, receiving all inpatient cancer treatment at a SCC was associated with superior overall survival (EWS HR 0.49, CI 0.37-0.67; OS HR 0.78, CI 0.63-0.97). Our results suggest that treatment for EWS and OS at a SCC is associated with significantly improved survival even after adjustment for known prognostic factors. The superior survival among those treated at SCCs may be due to having greater ac